Development and testing of a bovine trichomoniasis vaccine

Eighteen culled dairy cows were randomly allocated into 1 of 5 treatment groups. Six cows were vaccinated twice (2V), 21 days apart, 3 with whole cell (2WC) and 3 with fragmented cell membrane (2FC) containing 1 x 10(9)Trichomonas fetus organisms or protein equivalent in a commercial mineral oil adjuvant vaccine. Six more cows were vaccinated once (1V), 3 with whole cell (1WC) and 3 with fragmented cell vaccine (1FC), using the same vaccine, while 6 cows were used as the unvaccinated controls. All cows were challenged with 1 x 10(5) organisms 4 weeks after the second or the only vaccination. After challenge, cervico-vaginal mucus (CVM) samples were cultured for T . fetus weekly for 9 weeks. Whole cell vaccines were superior to fragmented cell vaccines, and both performed better than no vaccination for apparent elimination of trichomonad infections in dairy cows. In addition, 2V was superior to 1V, which, in turn, was superior to no vaccination. Furthermore, clearance time was reduced most by 2V and whole cell vaccination compared with 1V and fragmented cell vaccination. Clearance time was decreased significantly in all vaccinated cows compared with that in unvaccinated cows.     

Immunization in heifers with dual vaccines containing Tritrichomonas foetus and Campylobacter fetus antigens using systemic and mucosal routes

Vaccines against both bovine venereal campylobacteriosis and trichomonosis were tested. Heifers were assigned to three groups. Groups 1 (n = 21 heifers) and group 2 (n = 20) received a commercial or experimental vaccine, respectively, containing both Campylobacter fetus and Tritrichomonas foetus antigens. Group 3 (n = 21) received adjuvant alone. Preparations were injected SQ in groups 1 and 3 at days -60 and -30 (day 0 was considered the first day of a 90-day breeding period), and in group 2 SQ at days -30 and +11 and into the vaginal submucosa at day -9. Heifers were exposed to two pathogen-infected bulls for 90 days (from day 0 to day +90); furthermore, half of the heifers in each group were challenged at day +39 by an intravaginal instillation of C. fetus venerealis and T. foetus. Pregnancy diagnosis, vaginal culture, and determination of systemic IgG for both organisms were performed. Compared to controls, vaccinated heifers resisted or quickly cleared both pathogens, had a higher pregnancy rate and a higher systemic immune response during and after the breeding period. Overall, the experimental vaccine was superior to the commercial vaccine (groups 2 and 1, respectively). In conclusion, an experimental vaccine containing both C. fetus and T. foetus antigens, given both SQ and intravaginal immediately before breeding and early in the breeding season, yielded superior protection for heifers exposed to bulls harboring C. fetus and T. foetus.     

The effect of infectious bovine rhinotracheitis vaccine on reproductive efficiency in cattle vaccinated during estrus

Nineteen nulliparous, sexually mature heifers free of antibody to infectious bovine rhinotracheitis (IBR) virus were given two 35 mg intramuscular injections of Lutalyse 10 days apart to synchronize estrus and randomly divided into control and vaccinated groups. On the day of the last Lutalyse injection, modified live IBR virus vaccine was administered intramuscularly to each animal in the vaccinated group and each group was placed with a proven sire for 35 days. After the vaccination, samples were taken for isolation of virus and for determination of serum neutralizing antibody titers. No virus shedding occurred after intramuscular vaccination. However, the conception rate was markedly lower in the vaccinated group than in the control group. These results suggest that the intramuscular inoculation of modified live IBR virus vaccines into cattle during estrus is contraindicated.     

Effects of dry season nutritional supplementation on growth, onset of puberty and subsequent fertility in Boran and Boran x Friesian heifers in Ethiopia

Shortly after weaning at 8 months of age, 43 Boran and 46 Boran x Friesian crossbred heifers were randomly divided to either receive a supplementary feed containing 16% crude protein during the dry season or to serve as controls. Heifers were examined monthly, and data on body weight, wither height and body condition score were recorded. Ovarian size and structures were determined per rectum and heifers were kept under continuous observation for standing estrus. Blood samples were collected at 10-day intervals every month for determination of plasma progesterone levels. All heifers were exposed to intact bulls for 4 months after they attained 18 months of age. Average daily weight gain to puberty was significantly (P<0.01) higher in heifers given supplementation than in the controls (360 vs 326 g/day). The average daily weight gain in Boran heifers (296 g/day) was significantly (P<0.01) lower than in crossbred (392 g/day) heifers. Mean age at puberty differed significantly (P<0.001) between heifers given supplementation (573 days) and the controls (627 days). Boran heifers attained puberty at a significantly later age (660 vs 540 days; P<0.001) than crossbred heifers. Body weight at puberty did not differ between supplemented and control heifers (226 vs 222 kg); while the difference between Boran and crossbred heifers was significant (216 vs 232 kg; P<0.01). Pelvic size and body condition score were not influenced by supplementation but differed significantly between genotypes. Pregnancy rate after 4 months of breeding was higher in supplemented (79%) than in control (64%) heifers. Boran heifers had a significantly (P<0.001) lower pregnancy rate than crossbred heifers (52 vs 91%). Mean age and body weight at conception were not affected by supplementation but differed significantly (P<0.05) between genotypes. The results indicate that prepubertal supplementary feeding during the dry season increased growth rate, reduced age at puberty and improved fertility in both Boran and Boran x Friesian heifers.     

Effect of selenium and vitamin E supplementation during the late pregnancy on reproductive indices and milk production in heifers

A trial was performed to determine the effects of supplementation of selenium (Se) and vitamin E (VE) on reproductive indices and milk production in Holstein heifers. Sixty heifers at the late stage of gestation were randomly assigned into three groups. Heifers were balanced for age, weight and time of calving. Four and 2 weeks before expected calving the heifers were injected 0 ml (C), 20 ml (T1), and 40 ml (T2) Se and VE supplements. Each ml contained 0.5mg Se and 50 IU of D, L-alpha-tocopheryl acetate. Blood samples were collected from heifers 4 weeks before expected calving and at calving day. Se concentrations in serum and colostrums were measured. The reproductive parameters were recorded. The effects of Se and VE supplements on somatic cell count (SCC) and milk yield also were measured. Supplementation of Se increased the level of Se in serum of treated heifers at calving day (P<0.05). Se concentration of colostrums were affected by the treatments (P<0.05). Concerning reproductive performance of treated heifers; gestation length was similar among groups but in comparison with controls, T1 and T2 had no incidence of retained fetal membrane (i.e., beyond 12h.). In addition, open days were fewer in T1 and T2 heifers and the number of services per conception was fewer in T2 compared with controls (P>0.05). Daily milk production at 8 weeks lactation was significantly increased in T2 compared with controls (P<0.05). Likewise, the milk SCC decreased in treated heifers compared with controls (P<0.05).     

Detection of progeny immune responses after intravenous administration of DNA vaccine to pregnant mice

A number of factors influence the development of tolerance, including the nature, concentration and mode of antigen presentation to the immune system, as well as the age of the host. The studies were conducted to determine whether immunizing pregnant mice with liposome-encapsulated DNA vaccines had an effect on the immune status of their offspring. Two different plasmids (encoding antigens from HIV-1 and influenza virus) were administered intravenously to pregnant mice. At 9.5 days post conception with cationic liposomes, injected plasmid was present in the tissues of the fetus, consistent with trans-placental transfer. When the offspring of vaccinated dams were immunized with DNA vaccine, they mounted stronger antigen-specific immune responses than controls and were protected against challenge by homologous influenza virus after vaccination. Moreover, such immune responses were strong in the offspring of mothers injected with DNA plasmid 9.5 days after coitus. These results suggest that DNA vaccinated mothers confer the antigen-specific immunity to their progeny. Here we describe the methods in detail as they relate to our previously published work. Published: April 23, 2002     

Investigations of the incidence of bovine trichomoniasis in nevada and of the efficacy of immunizing cattle with vaccines containing Tritrichomonas foetus

Trichomonas cultures taken from 2389 bulls showed that approximately 4.7% of them were infected. Correlation of these data with the ranches from which diagnostic samples were obtained indicated that in the period of 1984 through 1987 26.7 to 44.1% of ranches had at least one infected bull. Thirty-four 18-month-old Holstein heifers were assigned to one of three groups, controls n = 12 animals, soluble vaccine n = 11 animals, and whole vaccine n = 11 animals to determine the effect of Tritrichomonas foetus vaccines on the reproductive performance of T . foetus infected animals. Heifers were bred with T . foetus infected bulls beginning two weeks after the second T . foetus vaccination. All immunized animals developed antibody titers of at least 1:1000 following vaccination. In addition, all control and immunized animals became infected with T . foetus . However, the duration of infection was approximately two weeks shorter in immunized animals. Approximately 42% (5 of 12) of control heifers remained infected with T . foetus for the duration of the experiment, while only 18% (2 of 11) of each of the vaccine groups remained infected for the duration of the experiment. Finally, 27% (3 of 11) of heifers in each of the vaccine groups were pregnant at slaughter, while none of the control heifers were pregnant at slaughter. Therefore, both vaccine formulations appeared to protect heifers (P<0.05) from fetal loss due to trichomoniasis.     

Efficacy of live B1 or Ulster 2C Newcastle disease vaccines simultaneously vaccinated with inactivated oil adjuvant vaccine for protection of Newcastle disease virus in broiler chickens

Two hundred, one-day-old broiler chicks were divided into groups 1, 2 and 3 containing 60, 70 and 70 chicks, respectively. The groups were divided into subgroups of 10 chicks that were vaccinated according to the following scheme: group 1 unvaccinated control, group 2 vaccinated subcutaneously at 1 day old with inactivated oil adjuvant vaccine (IOAV) in combination with live B1 vaccine. Group 3 was vaccinated in the same mode as group 2 with IOAV and live Ulster 2C vaccine. All birds were challenged when they were 28 days old. Mortality rate, body weight gain and feed conversion ratio (FCR) were monitored before and after challenge. All the chickens in group 1 died, indicating that there was no disease resistance of this unvaccinated control group of chickens. Conversely, the monitored disease resistance of chickens in groups 2 and 3 was 68.57% ± 18.64 and 88.57% ± 9.00, respectively (P < 0.05). The morbidity of chickens in groups 2 and 3 was 37.89% ± 14.36 and 14.76% ± 12.40, respectively (P < 0.05). The body weight gain, feed intake and FCR of group 3 were significantly better than those of group 2 (P < 0.05) during 1–42 days old. The simultaneous vaccination with B1 or Ulster 2C and IOAV of 1-day-old chicks gave some protection of 28-day-old broilers without a booster vaccination.     

Effects of sire and dam genotype for complex vertebral malformation (CVM) on risk of return-to-service in Holstein dairy cows and heifers

The emergence of a new hereditary disease, called "Complex vertebral malformation" (CVM), has been described in Holstein cattle population. This paper studied the incidence of mating concerning Holstein dairy cattle with CVM in Brittany and the possible influences of CVM status for sires and dams on return-to-service at different intervals post-service in cows and heifers. It was carried out based on a set of data for first and second inseminations between 1998 and 2001 in cows (n=530,538) and heifers (n=248,140). Incidence of matings between CVM gene carriers, between a carrier bull and a non-carrier cow and between a non-carrier bull and a carrier cow were estimated to be 1.4, 10.6 and 9%, respectively (1.1, 9.3 and 10.9%, respectively in heifers). Compared to CVM-free mating, the relative risk of return-to-service was increased when the sire was a CVM carrier and the dam was at risk of being a carrier, especially for late return (>25 days post-service). When the sire alone was a carrier, the relative risk was increased whenever the return occurred at a low but significant level. Following mating between a non-carrier bull and a dam at risk of being a carrier, the risk of return-to-service decreased at a low but significant level, whatever the interval in the heifers but only for 19-25 days intervals in the cows.     

Comparison of three commercial vaccines for preventing persistent infection with bovine viral diarrhea virus

Eighty crossbred beef heifers were randomly allocated to four groups to evaluate the efficacy of vaccination in preventing development of calves persistently infected with bovine viral diarrhea virus (BVDV). Group 1 (n = 11) was non-vaccinated controls, whereas three groups were vaccinated with commercially available multivalent BVDV vaccines at weaning (∼7 mo of age), 28 d post-weaning, ∼1 y of age, and 28 d later. Groups 2 (n = 23) and 3 (n = 23) were given a modified-live BVDV vaccine, whereas Group 4 was given an inactivated BVDV vaccine. Heifers were bred by AI and subsequently exposed to two bulls. At 61 d after AI, 70 heifers were pregnant (n = 10 for Group 1 and n = 20/group for Groups 2, 3, and 4). Three cattle persistently infected with BVDV were commingled with the pregnant heifers (in an isolated pasture) from 68 to 126 d after AI. Thereafter, viremias were detected in pregnant heifers from Groups 1, 3, and 4 (10/10, 1/20, and 10/20, respectively), but not in pregnant heifers from Group 2 (0/20). Resulting calves were assessed for persistent infection using serum PCR, ear notch antigen capture-ELISA, and immunohistochemistry. Persistently infected calves were only produced in Group 1 (10/10) and Group 4 (2/18). In conclusion, commercial vaccines provided effective fetal protection despite prolonged natural exposure to BVDV. Given that viremias were detected in 11 vaccinated heifers after BVDV exposure, and two vaccinated heifers gave birth to persistently infected calves, there is continued need for biosecurity and diagnostic surveillance, in addition to vaccination, to ensure effective BVDV control.     

Management of reproduction in dairy heifers based on the synchronization of estrous cycles

Israeli-Holstein breed dairy heifers (n = 571), 13 to 15 mo old, were utilized in two experiments. In Experiment 1, the reproductive performance of synchronized heifers was compared with that of untreated controls. The heifers in both groups were inseminated following the detection of estrus. In Experiment 2, all heifers were synchronized and inseminated following the detection of estrus. Half of the animals in this experiment also received one or two fixed-time inseminations 72 and 96 h after the last synchronization treatment. Synchronization of estrous cycles was performed by two prostaglandin F(2alpha) (PG) injections given 12 d apart. In the control group of Experiment 1, observation of estrous behavior and insemination of heifers detected in estrus were carried out daily throughout the experiment. In the synchronized groups of Experiments 1 and in 2, the management of reproduction consisted of estrus detection followed by the insemination of heifers in estrus carried out only during 6 d of every 3 wk. Five days following the second PG injection, 86% of the heifers were detected in estrus, 71% of them at 49 to 96 h after treatment. In Experiment 1, age at first insemination, age at conception, and conception rate were, respectively, 425 d, 446 d and 54% in the control group vs 432 d (P<0.02), 449 d and 62% in the PG-treated group. In Experiment 2, the respective figures were 436 d, 462 d and 59% in the group inseminated following the detection of estrus vs 427 d (P<0.002), 464 d and 51% (P<0.05) in the group in which heifers were inseminated at estrus and also received one or two fixed-time inseminations.     

Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice

 A replication-deficient recombinant vaccinia virus, NYVAC, was developed by deleting 18 open reading frames in the vaccinia virus genome. Recombinant NYVAC, encoding the murine T cell co-stimulatory gene B7.1 (CD 80) (NYVAC-B7.1) and the murine interleukin-2 gene (NYVAC-IL-2), were prepared and the expression of B7.1 and the secretion of IL-2 were respectively confirmed in vitro. The use of these viruses to prepare a potent tumor cell vaccine was studied in a syngeneic murine CC-36 colon adenocarcinoma model. Mice were immunized on days 1 and 8 with 10⁶ irradiated CC-36 cells that were infected with 10⁷ plaque-forming units of either NYVAC-B7.1, NYVAC-IL-2 or a control virus, NYVAC-HR, which encodes a vaccinia virus host-range gene. These mice were then challenged with 10⁸ viable CC-36 tumor cells on day 15. All mice (10/10) in a group that had received no vaccination and all mice (20/20) in a group that had received a control vaccine of CC-36/NYVAC-HR developed tumor 4-weeks after tumor cell challenge. Interestingly, only 16/20 mice in a group that had received CC-36/NYVAC-B7.1 showed the development of tumor after the same interval. The protection against tumor development and the reduction in tumor burden (as mean tumor diameter, 4 weeks after tumor challenge) were significant in this group when compared to groups that were either unvaccinated or vaccinated with CC-36/NYVAC-HR (mean tumor diameter = 6.51±3.2 mm compared to 26.5±0.9 mm or 26.2±1.8 mm respectively) (P = < 0.05). The protection against tumor in a group of mice that received CC-36/NYVAC-IL-2 vaccination was similar to that in the unvaccinated group or the group receiving a CC-36/NYVAC-HR control vaccination. However, in a survival experiment, mice that received either CC36/NYVAC-B7.1 or CC-36/NYVAC-IL-2 vaccination on the day of tumor transplantation survived significantly longer than mice that had not been vaccinated (median survival 60+ days, 60+ days or 23.5 days respectively) (P = <0.05). Interestingly, when a therapeutic tumor vaccination was performed on day 4 after tumor transplantation, mice that had been vaccinated with either CC36/NYVAC-B7.1 or CC-36/NYVAC-IL-2 did not show an improved survival when compared to mice in the control that had not been vaccinated (median survival 28 days compared to 26 days or 25 days respectively). However, mice that had received a therapeutic vaccination with CC-36 cells infected with both NYVAC-B7.1 and NYVAC-IL-2, 4 days after tumor transplantation, survived significantly longer than control mice that had not received any vaccination (median survival 29.5 days compared to 25 days respectively) (P<0.05). These results suggest that a replication-deficient recombinant NYVAC encoding the B7.1 gene and NYVAC encoding the IL-2 gene can be used to produce an effective vaccinia-virus-augmented tumor cell vaccine. Received: 2 March 1998 / Accepted 23 March 1998     

Protection of Spanish Ibex (Capra pyrenaica) against Bluetongue virus serotypes 1 and 8 in a subclinical experimental infection

Many wild ruminants such as Spanish ibex (Capra pyrenaica) are susceptible to Bluetongue virus (BTV) infection, which causes disease mainly in domestic sheep and cattle. Outbreaks involving either BTV serotypes 1 (BTV-1) and 8 (BTV-8) are currently challenging Europe. Inclusion of wildlife vaccination among BTV control measures should be considered in certain species. In the present study, four out of fifteen seronegative Spanish ibexes were immunized with a single dose of inactivated vaccine against BTV-1, four against BTV-8 and seven ibexes were non vaccinated controls. Seven ibexes (four vaccinated and three controls) were inoculated with each BTV serotype. Antibody and IFN-gamma responses were evaluated until 28 days after inoculation (dpi). The vaccinated ibexes showed significant (P<0.05) neutralizing antibody levels after vaccination compared to non vaccinated ibexes. The non vaccinated ibexes remained seronegative until challenge and showed neutralizing antibodies from 7 dpi. BTV RNA was detected in the blood of non vaccinated ibexes from 2 to the end of the study (28 dpi) and in target tissue samples obtained at necropsy (8 and 28 dpi). BTV-1 was successfully isolated on cell culture from blood and target tissues of non vaccinated ibexes. Clinical signs were unapparent and no gross lesions were found at necropsy. Our results show for the first time that Spanish ibex is susceptible and asymptomatic to BTV infection and also that a single dose of vaccine prevents viraemia against BTV-1 and BTV-8 replication.     

Resynchronization of previously timed-inseminated beef heifers with progestins

The objective was to determine the efficacy of a previously used CIDR or melengestrol acetate (MGA; 0.5mg/head/day) for resynchronization of estrus in beef heifers not pregnant to timed-AI (TAI). In three experiments and a field trial, heifers were reinseminated 6-12 h after first detection of estrus. Pregnancy diagnosis was done from approximately 25-43 days after either TAI or reinsemination. In Experiment 1, 79 heifers received a once-used CIDR from 13 to 20 days after TAI and 80 heifers were untreated controls. For these two groups, there were 34 and 35 heifers, respectively, not pregnant to TAI; median +/- S.E. intervals from TAI to onset of estrus were 22 +/- 0.2 days versus 20 +/- 0.6 days (P < 0.001); estrus rates were 70.6% versus 85.7% (P = 0.1); conception rates were 62.5% versus 76.7% (P < 0.3); and pregnancy rates were 44.1% versus 65.7% (P = 0.07), for CIDR and untreated (control) groups, respectively. In Experiment 2, heifers (n = 651) were TAI (Day 0) and 13 days later randomly assigned to one of seven groups (n = 93 per group) to receive a once-used CIDR (three groups; Days 13-20), MGA (three groups; Days 13-19), or no treatment (control group). Groups given a CIDR or MGA also received: no further treatment (CIDR or MGA alone); 1.5mg estradiol-17beta (E-17beta) and 50 mg progesterone (P4) in 2 mL canola oil on Day 13; or E-17beta and P4 on Day 13 and 0.5 mg E-17beta on Day 21 (24 h after CIDR removal or 48 h after the last feeding of MGA). Pregnancy rate to TAI was lowest (P < 0.05) for the group given a CIDR plus E-17beta and P4 on Day 13 and E-17beta on Day 21. Variability in return to estrus was greater (P < 0.001) in the control and MGA groups than in CIDR groups. Conception and pregnancy rates in heifers given a CIDR (65.1 and 61.4%) were higher (P<0.01) than those fed MGA (49.6 and 40.4%), but not different from controls (62.2 and 54.9%, respectively). In Experiment 3, 616 heifers received a once- or twice-used CIDR for 7 days, beginning 13+/-1 days after TAI, with or without a concurrent injection of 150 mg of P4 (2 x 2 factorial design). Pregnancy rate to TAI was 47.2%. In heifers that returned to estrus, there was no significant difference between a once- or twice-used CIDR for rates of estrus (68.8%, P < 0.3), conception (65.9%, P < 0.6) and pregnancy (45.3%, P < 0.8). Injecting progesterone at CIDR insertion increased the median interval from CIDR removal to onset of estrus (P < 0.05) and reduced rates of estrus (63.8% versus 73.8%, P<0.05), conception (60.5% versus 70.6%, P = 0.1) and pregnancy (38.6% versus 52.2%, P < 0.02). In a field trial, 983 heifers received a once-used CIDR for 7 days, beginning 13 +/- 1 days after TAI. Pregnancy rate to TAI was 55.2%. The median (and mode) of the interval from CIDR removal to estrus was 2.5 days. Estrus, conception and pregnancy rates were 78.2, 70.3 and 55.0% (overall pregnancy rate to TAI and rebreeding, 78.7%). In summary, a once- or twice-used CIDR for 7 days, starting 13 +/- 1 days after TAI resulted in the majority of nonpregnant heifers detected in estrus over a 4-day interval, with acceptable conception rates; however, injecting progesterone at CIDR insertion significantly reduced both estrus and pregnancy rates, and estradiol treatment after CIDR removal was associated with a decreased pregnancy rate to TAI. Fertility was higher in heifers resynchronized with a once-used CIDR than with MGA.     

Evaluation of a melengestrol acetate and prostaglandin F(2)alpha system for the synchronization of estrus in beef heifers

This study was conducted to determine the efficacy of feeding melengestrol acetate (MGA) for 14 days and administering prostaglandin F(2)alpha (PGF) 17 days after MGA to synchronize or induce estrus in yearling beef heifers. The study involved 56 Angus (n = 19), Hereford (n = 15) and Simmental (n = 22) heifers that were assigned by breed and pubertal status to either MGA+PGF or to control groups. Heifers in the synchronized group were fed 0.5 mg MGA per head per day for 14 days from a grain carrier and were injected with 25 mg, i.m. PGF 17 days after the last daily feeding of MGA. Control heifers were fed from a grain carrier without MGA and were not treated with PGF. Heifers were classified as pubertal when concentrations of progesterono in the serum exceeded 1 ng/ml in 1 of 2 samples collected prior to the initiation of treatments. Blood samples were collected 7 days before and on the day that treatment with MGA or carrier began and 7 days before and on the day that PGF was administered. Progesterone concentrations in the serum were elevated ( > 1 ng/ml) in 61% (17 28 ) of the MGA+PGF-treated heifers and in 61% (17 28 ) of the control heifers prior to feeding MGA. However, concentrations of progesterone in the serum at the time PGF was administered differed (P<0.05) between MGA+PGF and control groups. Concentrations of progesterone in the serum exceeded 1 ng/ml in 100% (28 28 ) of the MGA+PGF-treated heifers and in 71% (20 28 ) of control heifers at the time PGF was administered (P<0.05). All heifers were inseminated 12 hours after the first detected estrus. Twenty-two of 28 (79%) of the MGA+PGF-treated heifers exhibited estrus within 6 days after PGF compared with 9 of 28 (32%) of control heifers (P<0.05). The conception rate at first service did not differ between MGA+PGF and control groups (64% and 67%, respectively). Synchronized pregnancy rates were higher (P<0.05) for MGA+PGF-treated heifers than for control heifers (14 28 , 50% vs 6 28 , 21%). Increased concentrations of progesterone in serum at the time PGF was administered and higher pregnancy rates during the synchronized period among MGA+PGF-treated heifers demonstrate the efficacy of this treatment for use in estrus synchronization. Moreover, this treatment may have a potential effect on inducing puberty in breeding age heifers.     

Factors associated with first service conception in artificially inseminated nulliparous Holstein heifers

Animal and management factors associated with first service conception in nulliparous dairy heifers were determined in 601 Holstein heifers from a dairy farm in north central Florida. Animal data collected included body weight, height at the withers and tail head, body condition score at 6 months of age and just prior to first artificial insemination (AI), and pelvimetry measurements taken just prior to first AI. Management data included season of first AI, inseminator, service sire, method of estrus detection, whether the estrus of first insemination was induced using prostaglandin F(2alpha) (PGF(2alpha)), and whether the heifer received a modified live virus (MLV) vaccine within 21 days of first insemination. Data were analyzed using multivariable logistic regression. Heifers inseminated in the summer were more than four times less likely to become pregnant to first insemination than heifers bred during the rest of the year (odds ratio (OR)=0.24; 95% CI=0.14, 0.41). Using secondary signs for estrus detection instead of standing estrus resulted in significantly reduced odds of conception to first service (OR=0.37; 95% CI 0.13, 1.02). Also, heifers inseminated at estrus induced by PGF(2alpha) were approximately one-third less likely to conceive than those heifers inseminated to a naturally occurring estrus (OR=0.66; 95% CI 0.46, 0.95). An interaction between pelvic size and breeding season was found indicating that large pelvic size had a significant positive effect on fertility in the summer, but was not associated with conception to first service in the winter.     

Treating cattle with progesterone as well as a GnRH analogue affects oestrous cycle length and fertility.

Initiating the chronic administration of progesterone to cattle during metoestrus will produce shortened oestrous cycles containing one or two wave-like sequences of ovarian follicle development. Conception rates are reduced to inseminations at the oestrus preceding these shortened cycles. In contrast, a single injection of the GnRH analogue, buserelin, around mid-dioestrus can lengthen the oestrous cycle by increasing the proportion of cycles with three waves of follicular development and may also increase conception rates. A series of trials was conducted to test the hypothesis that the adverse effects of progesterone on oestrous cycle length and conception rate could be prevented with a strategic injection of GnRH. In Trial 1, progesterone was administered per vaginum to heifers for 10 days from Day 2 or 3 (Oestrus = Day 0) and with (n = 42) or without (n = 46) an injection of a GnRH analogue (10 microg buserelin) on Day 12 or 13. Other heifers (n = 44) served as an untreated control group. The average inter-oestrous interval (IOI) for those heifers treated only with progesterone was 17.0 days and was less (p<0.05) than the average intervals for those also receiving GnRH (20.2 days) or in the control group (20.0 days). In Trial 2, 45 heifers were inseminated following a synchronised oestrus. Progesterone was administered as in Trial 1 to 22 of the heifers. Their conception rate was 45.4% and this was less (p<0.05) than the 73.9% obtained with their 23 untreated contemporaries. Trial 3 was completed using 530 cows in commercial dairyherds. The 259 cows receiving progesterone and GnRH (buserelin) after their first inseminations had a conception rate of 68.3% compared to 56.1% for their 271 untreated herdmates (p<0.05%). Heifer calves born to treated cows had heavier birthweights (33.4 vs. 31.1 kg; p<0.05), but birthweights of bull calves were unaffected (35.5 vs. 35.8 kg). Gestation lengths for cows conceiving to first inseminations were similar for treated and control groups (280.9 vs. 280.5 days). The results of these trials confirmed the hypothesis that a strategic injection of the GnRH analogue, buserelin, could prevent the reductions in oestrous cycle length and conception rate associated with the chronic metoestrous administration of progesterone.     

Effect of clitoral stimulation after artificial insemination on conception in Zebu-crossbred heifers in the tropics

In order to increase conception rates to AI, an experiment was conducted to determine the effect of clitoral stimulation on pregnancy rate. Seven hundred and thrity-five Zebu-cross heifers were assigned to either of the following treatments: 1) control without clitoral stimulation (n=351) or 2) clitoral stimulation after IA (n=384). The data were analyzed using a linear model procedure. Clitoral stimulation increased pregnancy rates (57 vs 45 % for treated and control groups, respectively; P<0.02). Holstein x Zebu and Brown Swiss x Zebu heifers attained similar rates (P>0.05). There was a significant treatment-by-season interaction (P<0.01), with pregnancy rates being higher using clitoral massage during the rainy season (54.7 and 25.5% for the treated and control group respectively). In this study, manual clitoral stimulation increased conception rates in Zebu cross heifers under tropical conditions.     

Fertility on synchronized estrus in crossbred (Bos taurus x Bos indicus) heifers

This study was performed in Western Maharastra (India). The 272 crossbred heifers were randomly allocated within herds to one of the four following groups: 1) silastic coils, 10 days treatment (n = 65); 2) Norgestomet implants, 10 days treatment (n = 71); 3) prostaglandin F(2alpha) two injections 11 days apart (n = 70); and 4) control (n = 66). Almost all heifers in the treated groups were detected in heat during the four days following treatment (88-100%) vs 26% in the control group in the first 21 days. Mean conception rates at first AIs were respectively 62,48 and 60% in groups 1,2 and 4 (p > 0.05) and only 29% in group 3. By 90 days after treatment, 66, 59, 46 and 33 per cent of the females were pregnant for groups 1 to 4, respectively (p < 0.001). In conclusion, progestogen treatments seemed to be highly satisfactory both in terms of conception rates and intervals from treatment to pregnancy.     

Insemination management for a one-injection prostaglandin F(2)alpha synchronization system. II. One versus two inseminations following detection of estrus

Following detection of estrus in an estrus synchronization system, 216 dairy heifers were inseminated (A.I.) randomly either soon after detected estrus (1X) or soon after detected estrus and again 10 to 12 h later (2X). Average h from detection of estrus to A.I. was 1.8+/-0 for 1X and 1.1+/-0 and 11.1+/-0.4 for 2X. During the regimen, heifers were checked visually for estrus daily for five consecutive days with 16.0 and 17.3% showing estrus and receiving A.I. in the 1X and 2X groups, respectively. Those not seen in estrus were injected with 25 mg PGF(2)alpha with observations for estrus and A.I. continuing for five more days. Response rates as indicated by estrus following prostaglandin F(2)alpha (PGF(2)alpha) were 74.7 and 75.8% for 1X and 2X, respectively. Percentages of heifers in estrus <24, 25 to 48, 49 to 72, 73 to 96 and >96 h after PGF(2)alpha were 3.7, 22.8, 47.1, 15.4 and 11.0, respectively. Based on rectal palpation for pregnancy between 45 and 60 days after A.I., conception rates of 70.2% for 1X and 68.6% for 2X did not differ significantly (P>0.05). Progesterone concentrations at injection for heifers not responding to PGF(2)alpha were lower than was seen in responding heifers (2.7 vs 5.8 ng/ml) (P<0.01). Data from the present experiment supports the conclusion of an earlier experiment that satisfactory conception can be achieved with a single, established daily insemination period.